Sarepta Gene Therapy Risks - Search News

Order byBest matchMost fresh

News

Gene Therapy Stays on Market Despite FDA Request

· 2d · on MSN

Sarepta shares plunge 40% as future of its gene therapy appears at risk

Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy appeared at risk. Sarepta has reported three patient deaths related to its gene therapies.

Continue reading

· 2d · on MSN

Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys

· 1d · on MSN

Sarepta’s Risky Gamble: Gene Therapy Stays on Market Despite FDA Request

Fierce Biotech2d

UPDATED: Analysts demand transparency after Sarepta's roundabout disclosure of 3rd patient death

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

2d

Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On

Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results